A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM / Alliance A032101).
- Citation:
- J Clin Oncol vol 24 (16_suppl) TPS5118
- Meeting Instance:
- ASCO 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- A-DREAM
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- GU
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Epic Science
- Grants:
- U10CA180821, U10CA180882, UG1CA189823
- Corr. Author:
- Authors:
- Atish D. Choudhury Glenn Heller Melissa A. Reimers Andrew Laccetti Fabrice Smieliauskas Praful Ravi Katharine Dooley Gina L. Mazza Benjamin Gartrell Preston Steen Kayla Kroll Shiva Baghaie Archana Ajmera Thomas J. Smith Himisha Beltran Ronald Chen Rana R. McKay Matthew D. Galsky Jonathan E. Rosenberg Michael Morris
- Networks:
- CA249, KANSAS, LAPS-MA036, LAPS-MD017, LAPS-MO011, LAPS-NY016, MI020, MONTEFIORE, NY021, SANFORD
- Study
- Alliance-A032101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: